TrianglePhase 1 cancer trials
Safety, dose, how many people, how closely they are watched. Not a test of whether the treatment works.
This is not clinical evidence and not medical advice. It does not replace your care team. Discuss anything here with your clinician before you act on it. Product questions are on the FAQ.
What is a Phase 1 cancer trial?
Usually the first study of a new cancer treatment in people. It is built around safety, side effects, and dosing — not around proving the treatment works better than what is already used.
Does joining a Phase 1 trial mean standard care has failed?
Not automatically. Eligibility is written into the protocol. Some trials enrol people after standard options; others enrol earlier, in narrower settings. Read that on the ClinicalTrials.gov listing, with your care team.
How many people are in a Phase 1 cancer trial?
Small groups, typically around 15 to 30. Later phases grow: roughly 50 to 100 in Phase 2, and from a hundred to several thousand in Phase 3.
How closely are people watched in a Phase 1 trial?
Closely. Participants are monitored for unexpected side effects. If a safety concern comes up, the study is paused and examined. An institutional review board reviews the protocol before enrolment and at least yearly after that.
See recruiting Phase 1 trials →
Sources
- FDA: The Drug Development Process — Step 3: Clinical ResearchPhase 1 is primarily about safety, side effects, and dosing in people.
- NCI: How Do Clinical Trials Work?Phase 1 trials enrol around 15 to 30 people; Phase 2 50 to 100; Phase 3 from 100 to several thousand.
- NCI: Facts About Clinical TrialsPhase 1 participants are closely monitored for side effects and adverse events; a trial is stopped and examined if a safety concern arises.
- NCI: Are Clinical Trials Safe?IRBs review protocols before a trial accepts patients and yearly after that.